Bridgeway Capital Management’s Harvard Bioscience HBIO Stock Holding History

Bridgeway Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,250	Closed	-$5.48K	–	1245
2025 Q3	$5.48K	Hold	1,250	–	–	﹤0.01%	1196
2025 Q2	$5.55K	Sell	1,250 -7,702	-86%	-$32.2K	﹤0.01%	1180
2025 Q1	$50.7K	Sell	8,952 -3,980	-31%	-$51K	﹤0.01%	1120
2024 Q4	$273K	Sell	12,932 -5,518	-30%	-$127K	0.01%	945
2024 Q3	$496K	Hold	18,450	–	–	0.01%	863
2024 Q2	$526K	Hold	18,450	–	–	0.01%	847
2024 Q1	$782K	Sell	18,450 -1,390	-7%	-$62.5K	0.02%	810
2023 Q4	$1.06M	Hold	19,840	–	–	0.02%	742
2023 Q3	$853K	Hold	19,840	–	–	0.02%	751
2023 Q2	$1.09M	Hold	19,840	–	–	0.03%	708
2023 Q1	$833K	Sell	19,840 -2,500	-11%	-$74.2K	0.02%	765
2022 Q4	$619K	Sell	22,340 -4,960	-18%	-$122K	0.02%	847
2022 Q3	$699K	Sell	27,300 -1,060	-4%	-$35.1K	0.02%	811
2022 Q2	$1.02M	Buy	28,360 +5,808	+26%	+$262K	0.02%	724
2022 Q1	$1.4M	Sell	22,552 -17,360	-43%	-$1.03M	0.03%	697
2021 Q4	$2.81M	Sell	39,912 -3,000	-7%	-$213K	0.05%	497
2021 Q3	$3M	Hold	42,912	–	–	0.06%	467
2021 Q2	$3.58M	Buy	42,912 +8,920	+26%	+$631K	0.06%	412
2021 Q1	$1.86M	Sell	33,992 -6,760	-17%	-$329K	0.03%	648
2020 Q4	$1.75M	Sell	40,752 -14,750	-27%	-$551K	0.04%	567
2020 Q3	$1.67M	Sell	55,502 -7,500	-12%	-$252K	0.04%	489
2020 Q2	$1.95M	Buy	63,002 +380	+0.6%	+$10.2K	0.04%	428
2020 Q1	$1.38M	Sell	62,622 -1,940	-3%	-$52.6K	0.03%	457
2019 Q4	$1.97M	Hold	64,562	–	–	0.03%	564
2019 Q3	$1.99M	Buy	64,562 +10,430	+19%	+$259K	0.03%	512
2019 Q2	$1.08M	Sell	54,132 -6,320	-10%	-$185K	0.01%	712
2019 Q1	$2.6M	Sell	60,452 -3,490	-5%	-$127K	0.03%	440
2018 Q4	$2.03M	Buy	63,942 +2,020	+3%	+$79.6K	0.03%	503
2018 Q3	$3.25M	Sell	61,922 -15,070	-20%	-$846K	0.03%	449
2018 Q2	$4.12M	Hold	76,992	–	–	0.04%	366
2018 Q1	$3.85M	Sell	76,992 -6,600	-8%	-$296K	0.04%	364
2017 Q4	$2.76M	Buy	83,592 +5,030	+6%	+$170K	0.03%	490
2017 Q3	$2.95M	Buy	78,562 +7,940	+11%	+$235K	0.03%	447
2017 Q2	$1.8M	Buy	70,622 +19,150	+37%	+$474K	0.02%	615
2017 Q1	$1.34M	Buy	51,472 +14,570	+39%	+$420K	0.02%	710
2016 Q4	$1.13M	Buy	36,902 +11,500	+45%	+$293K	0.01%	772
2016 Q3	$691K	Buy	25,402 +290	+1%	+$8.05K	0.01%	951
2016 Q2	$718K	Hold	25,112	–	–	0.01%	898
2016 Q1	$758K	Hold	25,112	–	–	0.01%	883
2015 Q4	$871K	Buy	25,112 +5,000	+25%	+$171K	0.02%	818
2015 Q3	$760K	Sell	20,112 -35	-0.2%	-$1.63K	0.02%	845
2015 Q2	$1.15M	Hold	20,147	–	–	0.02%	730
2015 Q1	$1.17M	Buy	20,147 +35	+0.2%	+$1.88K	0.02%	720
2014 Q4	$1.14M	Hold	20,112	–	–	0.03%	723
2014 Q3	$823K	Hold	20,112	–	–	0.02%	836
2014 Q2	$915K	Hold	20,112	–	–	0.02%	802
2014 Q1	$953K	Hold	20,112	–	–	0.03%	779
2013 Q4	$945K	Sell	20,112 -6,415	-24%	-$280K	0.03%	766
2013 Q3	$1.06M	Buy	26,527 +171	+0.6%	+$6.72K	0.04%	701
2013 Q2	$939K	Buy	+26,356	New	+$1.01M	0.04%	663

Other funds holding HBIO

WCM

Weber Capital Management San Francisco, California $100M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

CCM

Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM

Bridgeway Capital Management's HBIO Position: Q4 2025 in Review

Bridgeway Capital Management sold out of Harvard Bioscience (HBIO) in Q4 2025, closing a stake of 1,250 shares — an estimated $5.48K sold.

Bridgeway Capital Management first reported a position in HBIO in Q2 2013 and held it in 50 quarters. The position peaked at $4.12M in Q2 2018. 63 funds tracked by Wall St. Rank hold HBIO as of Q4 2025.

Bridgeway Capital Management reported no remaining Harvard Bioscience position as of Q4 2025 after selling out during the quarter.
Bridgeway Capital Management sold 1,250 Harvard Bioscience shares in Q4 2025, an estimated $5.48K.
Bridgeway Capital Management first reported a position in Harvard Bioscience in Q2 2013 and held it in 50 quarters.
Bridgeway Capital Management's Harvard Bioscience position peaked at $4.12M in Q2 2018.
63 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2025.

Based on Bridgeway Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.